Our Team
Investment Parameters
Contact Form
Angstrom Pharmaceuticals has developed proprietary drugs for the treatment of proliferative and invasive diseases such as cancer and wet age-related macular degeneration (ARMD). Pre-clinical data in accepted animal models has been obtained in all these diseases. The company’s lead drug, Ĺ6, has proven safe in a phase I trial and statistically significant efficacy has been shown in a phase I/II as well as a doubled blind, placebo controlled phase II trial for ovarian cancer. The company has met with the FDA on a phase III registration trial and is starting financing/partnering discussions to fund a final trial to achieve drug approval. Hamilton led Angstrom's first institutional financing, along with Solstice Capital and Pacific Gate.

CargoTech is a developer and manufacturer of proprietary technology for the perishable shipping industry. Their flagship product, AirLiner, is an innovative product that allows shipping companies to transport any type of perishable goods more safely and cost-effectively than with Styrofoam. AirLiner quickly and easily turns a cardboard box into a lightweight insulated package, eliminating the difficult and costly disposal issues associated with foam packaging. Hamilton BioVentures co-invested in CargoTech with E-Capital, Stone Canyon Ventures, and the strategic investment arm of United Parcel Service.
In December 2005 the company was sold to Cold Pack System, SAS (“CPS”) CargoTech’s French licensee for cash and stock. In the fall of 2006 Hamilton sold its remaining equity interest in CPS for cash to be received in 2007.

Ceregene, Inc.
Ceregene's primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene will focus initially on the treatment of Alzheimer's and Parkinson's diseases using in vivo gene delivery technology. In addition, the company will carry out pre-clinical development for additional neurodegenerative targets such as Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). Hamilton actively worked with Ceregene to bring about a $32 million Series B financing led by Alta Partners and MPM Capital, with participation by Hamilton, Cell Genesys [Nasdaq: CEGE], and California Technology Ventures. Ceregene recently completed a new $40 million Series C upround of financing led by Investor Growth Capital with participation of Hamilton and the other Series B investors.

Converge Medical, Inc. developed novel medical devices that enable d surgeons to rapidly perform less invasive surgery utilizing sutureless anastomoses systems. These devices represented an enabling technology for a variety of delicate surgical procedures, including coronary artery bypass grafting (CABG) and peripheral artery bypass. Hamilton co-invested in Converge with St. Paul Venture Capital, Forward Ventures, and JAFCO Ventures. Hamilton actively worked with the company to bring about a $25 million financing (in Q4 2003) led by Bank of America Ventures, with participation from Global Life Science Ventures and Tullis-Dickerson as well as existing investors (including Hamilton). The company failed its key clinical trial in 2005 and was liquidated.

Egea Biosciences
Acquired by Johnson & Johnson (NYSE: JNJ).

In May 2004, Egea was acquired by Johnson & Johnson, parent company of Centocor, Inc. In May 2003, Egea entered an exclusive research collaboration with Centocor, Inc. to develop optimized protein pharmaceutical products.

Egea Biosciences, Inc., led by world-renowned scientist Glen A. Evans, M.D., Ph.D., develops innovative genes, proteins and biomaterials for industry and medicine, using its innovative core technology in bioinformatics and genomic-engineering-platform technology. Hamilton was the only institutional investor in Egea until joined by the Johnson & Johnson Development Corp in 2002.

Entropic Communications (Formerly RF Magic)
RF Magic designs, builds, and sells complex, highly integrated systems-on-a-chip radio frequency integrated circuits (RFICs). The company is focused on standard product RFIC solutions across multiple, large volume markets. Its multi-tuner and transceiver RFICs are used in increasingly complex systems needed in consumer broadband and digital entertainment markets. Hamilton led the company's latest investment round; other investors include Conexant, Echostar, STMicroelectronics, Texas Instruments, CMEA, Granite Ventures, Anthem Venture Partners, Fina Ventures, and Waypoint Ventures.

Effective June 30, 2007, RF Magic was acquired by Entropic Communications, Inc. in an all-stock transaction.

Entropic Communications, a privately held corporation is the leading developer of LAN and WAN networking of multimedia for the connected home.

Kémia is a biopharmaceutical company developing novel classes of non-peptidic, small molecule drugs. These new medicines are designed to selectively modulate specific classes of protein-protein and protein-peptide (P-P) interactions--a mechanism recognized as a powerful approach to clinical therapy in numerous major diseases, but historically either inaccessible or accessible only through peptide or protein drugs delivered by injection. The company is in phase II trials with its lead drug in multiple indications. Hamilton invested in a Series B round lead by J.P. Morgan Partners, along with Forward Ventures, Alta Partners, Texas Pacific Group, Novartis BioVentures, and Novo. The company closed a Series C $31 million round in 20006 lead by Aberdare Ventures with new investors MedImmune Ventures and Red Abbey Venture Partners. Hamilton participated along with the Series B investors in the Series C round.

In April 2003, Mohomine was acquired by Kofax (www.kofax.com), a US-based division of Swiss-based DICOM Group plc (DCM.L), the global leader in the Electronic Data and Document Capture ("EDC") market.

Mohomine, an e-business software infrastructure company, provides products and solutions for unstructured data management. Mohomine's customers include Fortune 1000 enterprises as well as software companies that incorporate Mohomine's products into their own solutions through OEM relationships. Hamilton co-invested in Mohomine with Windward Ventures and In-Q-Tel, the venture arm of the Central Intelligence Agency.

PhotoThera, Inc.
PhotoThera has developed a proprietary, non-invasive, light-based therapy, called NeuroThera®, for the treatment of ischemic stroke. Hamilton led PhotoThera's Series A financing. In Q2 2004, Delphi Ventures led a $19 million Series B financing for Photothera, with participation from De Novo Ventures, Vertical Group, Solstice Capital, and Hamilton. In 2006, PhotoThera completed its pilot human trials on 120 patients and has now commenced its pivotal registration trial to include 660 patients in the U.S. and abroad. Also in 2006, Warburg Pincus lead a $30 million 2x upround in which Hamilton participated along with the other Series B investors.

Acquired by Beckman Coulter (NYSE: BEC).

Q3DM provides High Throughput Microscopy (HTM) platforms and optimized assays focused on alleviating substantial inefficiencies in the drug discovery and development process. Q3DM’s fluorescence-based sub-cellular imaging and analysis capabilities deliver rapid assay development and validation for an extensive range of applications. Q3DM’s patented drug-cell assay technologies include theoretical advances, software and hardware for high speed sub-micron autofocus, cellular image analysis, fluorescence light source stabilization, and image data management.

Santarus, Inc. (Nasdaq: SNTS)
Santarus (Nasdaq: SNTS) held its Initial Public Offering in April 2004.

Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders. The primary business strategy is to develop and market proprietary products with new formulations, enhanced delivery systems or expanded indications that are based on currently marketed products or compounds that have clinically demonstrated safety and efficacy. Hamilton invested in a Series D round lead by S.R. One (the venture arm of GlaxoSmithKline), along with J.P. Morgan, Domain Associates, St. Paul Venture Capital, Advent, and other life science investors.

Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.

Troika Networks
Troika Networks
Acquired by QLOGIC Corporation in the fourth quarter of 2005.

Troika Networks, Inc. is the leading developer of Networked Storage Service Platforms, which simplify the development and deployment of networked-based storage services. Troika's next-generation technology dramatically reduces the cost of managing networked storage, allowing applications to run at "wire speed" inside the storage network. Troika's experience and deep intellectual property portfolio was developed delivering its first product, the world's first multi-protocol storage controller. Hamilton co-invested in Troika alongside Anthem Venture Partners, DynaFund Ventures, Windward Ventures, and Draper Fisher Jurvetson.

Voyager Systems Inc.
Acquired by TriTech Software Systems.

Acquired by TriTech Software Systems in December 2003.

Voyager Systems Inc. enables public safety agencies to give officers in the field mobile access to critical databases and other sources of key information, allowing them to transmit and to receive data using off-the-shelf wireless and wired devices (PDAs, handsets, laptops, etc.). The Company’s competitive advantage stems from proprietary IP around its second-generation ASP service, as well as the substantial public safety market expertise of its management team. Hamilton lead Voyager's Series A financing in September 2002, co-investing with Forrest Binkley Brown, Shepherd Ventures, and GKM Ventures.